Announcements Trials
Browse Landscape

Phase

Phase 1 24Phase 2 23Phase 3 7Phase 1/2 5Phase EARLY_PHASE1 2Phase 4 2Phase NA 1

Status

Completed 5Terminated 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 4Gastrointestinal 1

Conditions

Melanoma 4Colorectal Cancer Metastatic 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Carboplatin 112Cisplatin 111pembrolizumab 110Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × Vemurafenib × Clear all
NCT03101254 2024-07-17

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

Dana-Farber Cancer Institute

Phase 1/2 Completed
5 enrolled 10 charts
Dermatologic

Melanoma

NCT04790448 2023-02-15

Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer

Sun Yat-sen University

Phase 1/2 Completed
37 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

NCT01959633 2022-02-24

VEMUPLINT

Fondazione Melanoma Onlus

Phase 1/2 Completed
11 enrolled
Dermatologic

Melanoma

NCT01512251 2020-08-17

BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma

University of California, San Francisco

Phase 1/2 Completed
8 enrolled 6 charts
Dermatologic

Melanoma

NCT02354690 2020-03-23

Vemurafenib and TIL Therapy for Metastatic Melanoma

Herlev Hospital

Phase 1/2 Completed
13 enrolled 12 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡